ClinicalTrials.gg

Program

BI 1819479

A development code. Also written as “BI 1819479 (C-14)”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Boehringer Ingelheim.

Furthest: phase 2, since Mar 22, 20246 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim60 open or runningphase 2since Mar 22, 2024Mar 15, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 15, 2021First study: phase 1 study in HealthyFirst studyNCT04801693 · 66 enrolled · Germany
  2. Jun 28, 2022Phase 1 study in HealthyNCT05440799 · 62 enrolled · Germany
  3. Jul 18, 20222 phase 1 studies in HealthyNCT05467475, NCT05469646
  4. Mar 22, 2024Phase 2 study in Idiopathic Pulmonary FibrosisNCT06335303 · 322 enrolled · United States, Argentina, Australia and more
  5. Jul 4, 2025Phase 1 study in HealthyNCT07065617 · 7 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07065617Healthy · United Kingdom1TerminatedOct 4, 20257
NCT06335303Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more2CompletedNov 25, 2025322
NCT05469646Healthy · Japan1CompletedDec 20, 202224
NCT05467475Healthy · Germany1CompletedJan 23, 202315
NCT05440799Healthy · Germany1CompletedAug 2, 202362
NCT04801693Healthy · Germany1CompletedApr 25, 202266

How it is read

Names in the registry

  • “BI 1819479”, 6 entries
  • “BI 1819479 (C-14)”, 1 entry

Codes read as this program: BI1819479.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.